TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01123863

Intervention type: OTHER
Intervention: Brigance Preschool Screen -II
Description: Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.

Intervention type: OTHER
Intervention: Brigance Preschool Screen -II
Description: Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child.~The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian.
Study: NCT03313427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Early Intervention
Description: At the UCIN:~* Parental education to empower them on motor development and parent-infant relationship. Consisted on 6 sessions during the first weeks at the NICU.~* Tactile and kinaesthetic stimulation managed by parents. 2 times a day, 15 minutes each, during 10 days.~At home:~Psychomotor Development Program for the baby; comprised of different exercises, in different phases, depending on child maturation stage. Started after hospital discharge until 2 months corrected age.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: NICU usual care
Study: NCT00890565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron
Description: Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: granisetron
Description: Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron
Description: Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
Study: NCT03368170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesdopetam (IRL790)
Description: Mesdopetam (IRL790) capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mesdopetam (IRL790)
Description: Mesdopetam (IRL790) capsule
Study: NCT00919035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: torisel
Description: Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion
Study: NCT02205749

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Study-specific consent model
Description: • Review plain language brochure describing consent to a biobank based on the study-specific model of consent

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Study-specific consent model
Description: • Review plain language brochure describing consent to a biobank based on the study-specific model of consent

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Study-specific consent model
Description: • Review plain language brochure describing consent to a biobank based on the study-specific model of consent

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Broad consent model
Description: • Review plain language brochure describing consent to a biobank based on the broad model of consent

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Broad consent model
Description: • Review plain language brochure describing consent to a biobank based on the broad model of consent

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Broad consent model
Description: • Review plain language brochure describing consent to a biobank based on the broad model of consent

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Notice consent model
Description: • Review plain language brochure describing consent to a biobank based on the notice model of consent

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Notice consent model
Description: • Review plain language brochure describing consent to a biobank based on the notice model of consent

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Notice consent model
Description: • Review plain language brochure describing consent to a biobank based on the notice model of consent
Study: NCT03957837

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical nerve sheath diameter ultrasound measurement
Description: In cases: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline before the induction of general anesthesia (5 min after the beginning of mechanical ventilation in supine position); (T2) after 10 min from 25 degrees head down positioning and with pneumoperitoneum insufflation; (T3) after 60 min from T2, in head down position; (T4) after 10 min from tracheal tube removal, in supine position.~In healthy controls: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline in supine position; (T2) after 10 min from 25 degrees head down positioning; (T3) after 60 min from T2, in a head down position; (T4) after 10 min from positioning supine

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical nerve sheath diameter ultrasound measurement
Description: In cases: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline before the induction of general anesthesia (5 min after the beginning of mechanical ventilation in supine position); (T2) after 10 min from 25 degrees head down positioning and with pneumoperitoneum insufflation; (T3) after 60 min from T2, in head down position; (T4) after 10 min from tracheal tube removal, in supine position.~In healthy controls: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline in supine position; (T2) after 10 min from 25 degrees head down positioning; (T3) after 60 min from T2, in a head down position; (T4) after 10 min from positioning supine
Study: NCT03616678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenTouch System
Description: The VenTouch™ System consists of a delivery tool with a pre-loaded implant (VenTouch device) and accessories, which include a sizing tool, PEMS, chamber positioning tool, and accessories kit with luer fitting, tubing clamp, and titanium plug. The VenTouch device is offered in 6 sizes, with 4 different sized inflatable chambers available. Please refer to the VenTouch Instructions for Use for and system details.~The VenTouch device consists of three (3) inflatable silicone chambers attached to the wall of a knitted polyester support. The VenTouch device is implanted around the base of the heart and positioned at the level of the atrio-ventricular (AV) groove and the adjacent ventricular muscle. The VenTouch device is composed of biocompatible, medical-grade silicone and polyester.
Study: NCT03504878

Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.

Intervention type: PROCEDURE
Intervention: Open appendectomy
Description: The open appendectomy was carried out in the standard way with McBurney muscle splitting incision.
Study: NCT02355288

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Coronary Bypass
Description: Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutenous Coronary Intervention
Description: Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
Study: NCT02597946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT04448587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg
Description: Oral sitagliptin will be commenced at a dose of 100 mg BID. The dose will be increased by 100 mg every three days up to a maximal dose of 300 mg BID. In the case of significant drug related side effects or drug intolerance, the last tolerated dose will be resumed. Patients responding well to lower doses of sitagliptin, will not be given higher doses of the drug. Sitagliptin will be provided as long as deemed effective by the treating physician up to three months.
Study: NCT03105687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders of medicines intake
Description: The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.
Study: NCT03766048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-Anterior-Mesh, SAM
Description: laparoscopic sacropexy is only performed with the anterior mes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Double-Mesh, DM
Description: laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space
Study: NCT02915081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light
Description: Illumination: High illumination lighting will be instituted with a Day\*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period.
Study: NCT02730884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rigosertib
Description: Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
Study: NCT03157427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRYOBEAUTY MAINS
Description: CYOBEAUTY MAINS diffuses Difluoroethane gas to the skin. The administration of the cryogenic gas is temperature controlled, accurate and contactless (by means of a spray nozzle), in small quantity (\<1g) and during a predetermined short duration (3 seconds)
Study: NCT04313127

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
Description: Intramuscular other name:Ad5-nCoV
Study: NCT02823691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide and Metformin
Description: Lanreotide and Metformin
Study: NCT04349527

Intervention type: PROCEDURE
Intervention: Round-block Oncoplastic Breast Conserving Surgeries
Description: We de-epithelize the gap between the double round-lines, and we dissect the dermis from the best localization where we can reach the tumor. If the tumor located close to the skin then we are not performing de-epithelization, we excise it with the skin. We mark every wall of the tumor bed with clips. We dissect the surrounding parenchyma- so called parenchyma pillars- from the pectoral fascia and the skin, and we mobilize it. The line under the skin means, the layer under the subcutis, above the superficial fascia, so gives appropriate blood supply to the skin. After this the incision line should be placed 5 mm from the outer round line, so a dermis pillar should be left, and the skin is dissected from the parenchyma as needed. The outer round line should be tightened with a non-absorbable running Benelli suture to fit the areola then interrupted sutures placed to make tensionless the running intracutaneous suture.

Intervention type: PROCEDURE
Intervention: Retroglandular Oncoplastic Breast Conserving Surgeries
Description: We incise the skin slightly lateral in the IMF, around 7 cm long. We dissect with electrocauther the parenchyma with the pectoral fascia from the pectoralis major muscle at least until the mamilla. We incise the fascia along with the parenchyma which contains the tumor and macroscopically 10 mm safe zone. If the tumor is palpable, we turn the parenchyma slightly inside-out, if not, we localize it at the maximum measurement detected according to the ROLL labeling. After marking the tumor bed, we directly adapt the surrounding parenchyma pillars with absorbable sutures, or inverting sutures, or if it requires, we adapt the tumor bed with so-called dual plane mobilization. After revision, we close the fascia with absorbable running suture over the Redon drain then subcutaneous running suture with absorbable suture and finally intracutaneous skin closure.
Study: NCT00216411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01998828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablet administered orally once daily
Study: NCT05088304

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT01661140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (stable dose)
Description: Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: 8 mg/kg intravenously every 4 weeks for 72 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg intravenously every 4 weeks for 72 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (tapering dose)
Description: Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
Study: NCT01554280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully coated, removable , self-expanding oesophageal stent
Description: Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
Study: NCT01240642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA404
Study: NCT03258112

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radiofrequency cardiac catheter ablation
Description: procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
Study: NCT04295161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate immediate release formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate immediate release formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate immediate release formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate immediate release formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate immediate release formulations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Abiraterone acetate immediate release formulations
Study: NCT01391000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LASER CO2
Description: The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.~Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA.
Study: NCT02918864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Skills Training
Description: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Play Therapy
Description: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Study: NCT05572762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cannula plastic part while applying peribulbar block
Description: Using the cannula and introducing it peribulbar to apply regional ophthalmic anesthesia avoiding by this causing trauma to the globe, as the normal globe consistency is marble-like, the cannula can't puncture except in case of presence of staphyloma, so the cannula will either curve around it or will be kinked causing failure of the technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional technique
Description: the patients are going to receive the local anesthetic standard of care technique by using 23- or 24-gauge needle introduced through the skin extra-conal and local anesthetic solution will be injected with volume AND concentration according to the surgery going to be done
Study: NCT02872623

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Enterography-MRI without enteroclysis

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: enteroCT with enteroclysis
Study: NCT01733472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA-arm, remifentanil
Description: Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RA-arm
Description: Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
Study: NCT02887391

Intervention type: OTHER
Intervention: No intervention - observational study
Description: No intervention - observational study

Intervention type: OTHER
Intervention: No intervention - observational study
Description: No intervention - observational study
Study: NCT02755857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lozanoc
Description: 65 mg